Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage Closes $72 Million B Round for Oncology Drug Program

publication date: Dec 27, 2016
Ascentage Pharma of China completed a $72 million Series B funding, led by SDIC Fund Management, a China state-sponsored investor. Ascentage is a clinical-stage pharma focused on developing small-molecule oncology drugs with apoptosis mechanisms. Yesterday, Ascentage announced its novel Bcl-2/Bcl-XL inhibitor was approved to begin clinical trials in the US, the company's sixth molecule to start clinical development. In 2015, Ascentage raised $15.5 million in initial venture funding. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital